Video

Dr. Lekakis on Managing the Toxicity of CAR T-Cell Therapy

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses managing the toxicity of CAR T-cell therapy.

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses ways of managing the toxicity of CAR T-cell therapy.

One of the biggest challenges with CAR T-cell therapy is the toxicity profile, as there are a number of unanswered questions, Lekakis says. For grade 3/4 neurotoxicity, high-dose steroids are typically given. Steroids may also be appropriate for patients with grade 2 neurotoxicity, says Lekakis. However, researchers don’t yet know the impact of corticosteroids on T cells.

One toxicity that researchers struggle with is a rare condition called cerebral edema, Lekakis notes. This is the most severe case of neurotoxicity a patient can develop. Cerebral edema occurs in 1% to 2% of patients treated with CAR T-cell therapy, but it is mostly fatal. Physicians currently manage this with corticosteroids in an attempt to induce hypocapnia, but it remains a major challenge.

Related Videos
Jacob Sands, MD
Martin H. Voss, MD
Amitkumar Mehta, MD
Sunil Adige, MD
Nitin Jain, MD
Kimmie Ng, MD, MPH
Marina Chiara Garassino, MD
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Rahul Banerjee, MD, FACP
Seth Wander, MD, PhD